MOLECULAR PARTNERS AG Stock Price, News & Analysis

Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced significant advancements in its Radio DARPin Therapy (RDT) platform, showcasing new preclinical data that highlights the technology's potential for targeted radionuclide delivery. The findings, which will be presented at the American Association for Cancer Research Annual Meeting on April 18, 2023, demonstrate reduced kidney accumulation and high tumor penetration of DARPins due to specific engineering. This innovative approach addresses historical safety concerns associated with small protein-based delivery vectors. The company aims to expand the use of RDT to a broader range of tumor targets, leveraging collaborations with major pharmaceutical firms such as Novartis.

Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) held its Annual General Meeting where shareholders approved all Board of Directors' motions. Key approvals included the financial statements for 2022 and the carry-forward of earnings totaling CHF 124 million, reducing prior losses from CHF 216 million to CHF 92 million. The Board received discharge for 2022, and all members were re-elected for another year. KPMG AG Zurich was confirmed as statutory auditors for 2023. The meeting also endorsed compensation motions for the Board and Management.

Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has announced its Annual General Meeting scheduled for April 4, 2023, at 14:00 CET in Schlieren, Switzerland. The meeting will provide insights into the company's developments and future directions. Key financial dates include the Interim Management Statement for Q1 2023 on May 11 and the Half-year results on August 24. The company focuses on developing DARPin therapeutics, custom-built proteins aimed at addressing unmet medical needs, particularly in oncology and infectious diseases, with partnerships established with major pharmaceutical firms.

Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) reported significant advancements in its 2022 corporate highlights and financial results. The company initiated a Phase 1 study for MP0533, a tri-specific T-cell engager targeting acute myeloid leukemia, and presented promising preclinical data at the ASH Annual Meeting. Financially, Molecular Partners achieved CHF 189.6 million in total revenues, a substantial increase from CHF 9.8 million in 2021, resulting in a net profit of CHF 117.8 million. The company maintains a strong cash position of CHF 249.1 million, expected to fund operations into 2026. 2023 guidance indicates operating expenses of CHF 70-80 million.

Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech firm specializing in DARPin therapeutics, will release its 2022 financial results on March 9, 2023, followed by an investor call on March 10, 2023. The call will summarize key highlights from Q4 and the full year. CEO Patrick Amstutz is scheduled to present at the 43rd Annual Cowen Health Care Conference on March 8, 2023, in Boston, MA. Investors can access a live webcast of the results presentation on the company’s website, with a replay available for 90 days thereafter.

Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced new preclinical data from its Radio DARPin Therapy Platform at the 12th International Symposium on Targeted Alpha Therapy (TAT 12) held on February 28, 2023, in Cape Town, South Africa.

The platform aims to enhance the delivery of radioactive payloads to tumors while minimizing kidney accumulation. Initial data indicate a significant reduction in kidney retention, allowing for higher doses of radioactivity at the tumor site without compromising therapeutic efficacy.

The company is advancing several in-house and partnered DARPin-based programs, addressing high unmet medical needs in oncology.

Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a biotech company focused on DARPin therapeutics, announced that its CEO, Patrick Amstutz, Ph.D., will be speaking at the SVB Leerink Global Healthcare Conference on February 15, 2023, at 12:00 pm ET. The presentation will provide insights into the company's clinical-stage advancements and partnerships within oncology and infectious diseases. A webcast and replay will be accessible on their official website. Molecular Partners AG aims to address challenges that existing drug modalities cannot, with several compounds in various stages of development.

Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced the initiation of a Phase 1 first-in-human study for its candidate MP0533, targeting acute myeloid leukemia (AML). The trial will assess the safety, tolerability, and efficacy of MP0533, which employs a novel mechanism that selectively engages CD3 on T cells when binding two or three tumor-associated antigens. This approach aims to enhance targeting of leukemic cells while sparing healthy ones. The study plans to enroll 20-45 patients with relapsed/refractory AML across five sites in Switzerland and the Netherlands.

Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced progress in its infection and oncology portfolios, highlighting the development of a DARPin Radioligand Therapy platform targeting DLL3, a protein associated with certain tumors. The company reported unaudited cash reserves of approximately CHF249 million, expected to last until 2026. A collaboration with Novartis aims to address global health threats. Upcoming milestones include patient recruitment for clinical studies in early 2023 and a first data readout for the MP0533 study.